NASDAQ:LNTH - Lantheus Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lantheus Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $20.44 -0.07 (-0.34 %) (As of 12/6/2019 04:00 PM ET) Add Compare Today's Range$20.38Now: $20.44▼$20.8950-Day Range$18.74MA: $20.38▼$21.5552-Week Range$13.82Now: $20.44▼$29.80Volume302,601 shsAverage Volume377,423 shsMarket Capitalization$802.23 millionP/E Ratio21.74Dividend YieldN/ABeta1.43 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LNTH Previous Symbol CUSIPN/A CIK1521036 Webhttp://www.lantheus.com/ Phone978-671-8001Debt Debt-to-Equity Ratio1.84 Current Ratio2.59 Quick Ratio2.08Price-To-Earnings Trailing P/E Ratio21.74 Forward P/E Ratio20.44 P/E Growth1.74 Sales & Book Value Annual Sales$343.37 million Price / Sales2.34 Cash Flow$1.33 per share Price / Cash Flow15.34 Book Value$1.85 per share Price / Book11.05Profitability EPS (Most Recent Fiscal Year)$0.94 Net Income$40.51 million Net Margins10.02% Return on Equity46.58% Return on Assets9.66%Miscellaneous Employees488 Outstanding Shares39,248,000Market Cap$802.23 million Next Earnings Date2/18/2020 (Estimated) OptionableOptionable Receive LNTH News and Ratings via Email Sign-up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:LNTH Rates by TradingView Lantheus (NASDAQ:LNTH) Frequently Asked Questions What is Lantheus' stock symbol? Lantheus trades on the NASDAQ under the ticker symbol "LNTH." How were Lantheus' earnings last quarter? Lantheus Holdings Inc (NASDAQ:LNTH) issued its quarterly earnings data on Thursday, October, 31st. The medical equipment provider reported $0.28 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $0.07. The medical equipment provider earned $85.80 million during the quarter, compared to the consensus estimate of $83.82 million. Lantheus had a net margin of 10.02% and a return on equity of 46.58%. Lantheus's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.24 earnings per share. View Lantheus' Earnings History. When is Lantheus' next earnings date? Lantheus is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Lantheus. What guidance has Lantheus issued on next quarter's earnings? Lantheus issued an update on its fourth quarter earnings guidance on Thursday, October, 31st. The company provided earnings per share guidance of $0.27-$0.30 for the period, compared to the Thomson Reuters consensus estimate of $0.34. The company issued revenue guidance of $89-$91 million, compared to the consensus revenue estimate of $92.84 million. What is the consensus analysts' recommendation for Lantheus? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus. Has Lantheus been receiving favorable news coverage? News stories about LNTH stock have been trending very positive this week, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Lantheus earned a news impact score of 3.6 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Lantheus. Are investors shorting Lantheus? Lantheus saw a decline in short interest in November. As of November 15th, there was short interest totalling 1,210,000 shares, a decline of 9.7% from the October 31st total of 1,340,000 shares. Based on an average daily trading volume, of 411,400 shares, the short-interest ratio is currently 2.9 days. Approximately 3.2% of the shares of the company are short sold. View Lantheus' Current Options Chain. Who are some of Lantheus' key competitors? Some companies that are related to Lantheus include Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Heska (HSKA), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Riot Blockchain (RIOT), Trinity Biotech (TRIB), GeneNews (GNWSF) and Arca Biopharma (ABIO). What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include Mobileye (MBBYF), CBL & Associates Properties (CBL), Energy Transfer LP Unit (ET), Gerdau (GGB), Cypress Semiconductor (CY), Akorn (AKRX), Ares Capital (ARCC), Endocyte (ECYT), Exelixis (EXEL) and Paratek Pharmaceuticals (PRTK). Who are Lantheus' key executives? Lantheus' management team includes the folowing people: Ms. Mary Anne Heino, CEO, Pres & Director (Age 59)Mr. Robert J. Marshall Jr., CFO & Treasurer (Age 52)Mr. Michael P. Duffy, Sr. VP of Law & Public Policy, Gen. Counsel and Sec. (Age 58)Dr. Cesare Orlandi, Chief Medical Officer (Age 69)Mr. John J. Bolla, Chief Operating Officer (Age 49) When did Lantheus IPO? (LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Lantheus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (3.76%), Vaughan Nelson Investment Management L.P. (3.49%), Tamarack Advisers LP (1.91%), Voya Investment Management LLC (1.68%), Rice Hall James & Associates LLC (1.09%) and Peregrine Capital Management LLC (0.56%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno, Timothy G Healey and Tudor Brown. View Institutional Ownership Trends for Lantheus. Which institutional investors are selling Lantheus stock? LNTH stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Vaughan Nelson Investment Management L.P., Dupont Capital Management Corp, Campbell & CO Investment Adviser LLC, Cadence Capital Management LLC, Hancock Whitney Corp, State Street Corp and Bowling Portfolio Management LLC. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown. View Insider Buying and Selling for Lantheus. Which institutional investors are buying Lantheus stock? LNTH stock was acquired by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, Rice Hall James & Associates LLC, Russell Investments Group Ltd., State of New Jersey Common Pension Fund D, Tealwood Asset Management Inc., Hussman Strategic Advisors Inc., Chicago Equity Partners LLC and Squarepoint Ops LLC. View Insider Buying and Selling for Lantheus. How do I buy shares of Lantheus? Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Lantheus' stock price today? One share of LNTH stock can currently be purchased for approximately $20.44. How big of a company is Lantheus? Lantheus has a market capitalization of $802.23 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus. What is Lantheus' official website? The official website for Lantheus is http://www.lantheus.com/. How can I contact Lantheus? Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected] MarketBeat Community Rating for Lantheus (NASDAQ LNTH)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 258 (Vote Outperform)Underperform Votes: 238 (Vote Underperform)Total Votes: 496MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/7/2019 by MarketBeat.com StaffFeatured Article: Call Option